Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.
"We are extremely pleased to establish a new collaboration with Janssen, an innovative leader in antibody-based approaches for therapeutic intervention of disease processes," commented Dr. Duccio Neri, Philogen's CEO.
No financial details of the agreement were released.